Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease
Indexed incrossrefpubmed
Abstract
Alzheimer's disease (AD), the most common cause of adult-onset dementia is characterized by a progressive decline of cognitive functions accompanied by behavioral manifestations. The main class of drugs currently used for the treatment of AD are acetylcholinesterase/cholinesterase inhibitors (ChE-Is). The first ChE-I licensed for symptomatic treatment of AD was tacrine. The ChE-Is currently available in the market are donepezil, rivastigmine and galantamine as tacrine is no longer in use, due to its hepatotoxicity. According to mechanism of action the ChE-Is are classified as short-acting or reversible agents such as tacrine, donepezil, and galantamine, as intermediate-acting or pseudo-irreversible agent such…
Citation impact
1,055
total citations
- FWCI
- 61.37
- Percentile
- 100%
- References
- 156
Citations per year
Authors
6Topics & keywords
Topics
Keywords
- Tacrine
- Donepezil
- Galantamine
- Rivastigmine
- Acetylcholinesterase
- Pharmacology
- Cholinesterase
- Memantine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.